Laura Mertens on Muck Rack

Laura Mertens

Solingen
As seen in: Rheinische Post, Solingen Magazin, Nature, MDPI, WDR, The Lancet, Physical Review B, European Urology, EJSO - European Journal of Surgical Oncology, BJU International Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Laura

Contact Laura, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Worse bladder cancer outcomes in women than in men — bias, biology or both?

|
By Niyati Lobo, Laura Mertens, Tahlita C. M. Zuiverloon
| Nature Verified
Women with bladder cancer face differences in diagnosis and treatment and have worse outcomes than men despite lower incidence. This disparity cannot be univocally ascribed to bias or biology but reflects a convergence between these two aspects across diagnostic pathways, treatment delivery and tumour biology. Addressing these issues demands a coordinated, multi-pronged action across research, clinical practice and health policy.
Open in Who Shared Issue with article?

Systemic induction therapy and the expanding frontier of bladder preservation in MIBC

|
By Laura Mertens, Ashish M. Kamat
| Nature Verified
Two recent phase II trials, INDIBLADE and SURE-02, challenge the long-standing paradigm of mandatory radical local therapy for muscle-invasive bladder cancer (MIBC). As increasingly potent systemic induction treatment strategies emerge, a key question arises: can induction therapy response guide omission of radical surgery and radiotherapy to enable preservation of an intact, functioning bladder in selected patients?
Open in Who Shared Issue with article?
|
By Niyati Lobo, Roberto Contieri, Laura Mertens, Ashish M. Kamat
| European Urology Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Shore, N.D. ∙ Powles, T.B. ∙ Bedke, J. ... Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial Nat Med. 2025; 31:2806-2814 2. De Santis, M. ∙ Palou Redorta, J. ∙ Nishiyama, H. ... Durvalumab in combination with BCG for BCG-naive, high-risk, non–muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial Lancet.
Open in Who Shared Issue with article?
See all 35 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified